- ProQR to host an R&D day in
New Yorkon June 15from 8:00am to 1:00pm ET
- Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB)
- An update on the innovation/discovery pipeline including programs for Usher syndrome and other DEB mutations
- An introduction to ProQR’s novel RNA editing platform technology called Axiomer
The R&D Day will feature presentations by ProQR management on the progress on its pipeline, including a review and introduction of several near- and medium term value drivers. In addition, several leading opinion leaders will discuss the state of the art in research and development on critical areas of the company’s pipeline including CF, inherited blindness, debilitating skin diseases and RNA technologies.
“Following a significant effort to build a diversified product portfolio over the last 5 years, we now have a pipeline that includes two clinical programs, one pre-clinical program and two programs ready to enter development,” said
“Over the last several decades the RNA space has matured significantly. With our management and scientific resources we believe we are well positioned to unlock the field’s substantial potential,” said
R&D Day Event details
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 90 days following the presentation date.
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of our RNA technology, our innovation programs and pipeline, our discovery efforts and capabilities and our R&D day. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the
Chief Financial Officer
T: +1 415 231 6431